Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2010 | Original Paper

Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer

Authors: Xu Zhou, Wantao Chen, Yuexing Zhang, Jian Sun, Qing Wang, Youcheng Yu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2010

Abstract

Objective

An ErbB3-binding protein 1 (Ebp1), was shown to be a potent tumor suppressor in breast and prostate cancer cells. We hypothesized that the inhibitory properties of the Ebp1 gene could be beneficial if ectopically expressed in oral squamous cell carcinoma (OSCC) cells.

Methods

One OSCC cell line Tca8113 was stably transfected with the complete Ebp1 cDNA or the vector control pcDNA3.1. The inhibitory effect was evaluated using in vitro proliferation assay, cell cycle distribution and anchorage-independent growth in soft agar as well as in vivo tumorigenicity.

Results

Stable gene transfer was verified by Western Blot analysis and reverse transcription RT-PCR. Following transfection of Ebp1, a significant reduction in cell proliferation and anchorage-independent growth in soft agar were observed. Ectopic expression of Ebp1 led to a change in cell cycle profile and most importantly, a strong decrease in tumorigenicity of human OSCC cell line in a xenograft mouse model.

Conclusions

Ectopic expression of Ebp1 mediates multiple antitumor activities against OSCC, suggesting a potential of Ebp1-based novel therapy for clinical OSCC treatment.

Bernier J, Bentzen SM, Vermorken JB (2009) Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6:266–277CrossRefPubMed

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMed

Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987CrossRefPubMed

Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97:4227–4232CrossRefPubMed

Hamburger AW (2008) The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 13:225–233CrossRefPubMed

Horváth BM, Magyar Z, Zhang Y, Hamburger AW, Bakó L, Visser RG, Bachem CW, Bögre L (2006) EBP1 regulates organ size through cell growth and proliferation in plants. EMBO J 25:4909–4920CrossRefPubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed

Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24:2666–2672CrossRefPubMed

Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70–82CrossRefPubMed

Kim MM, Califano JA (2004) Molecular pathology of head-and-neck cancer. Int J Cancer 112:545–553CrossRefPubMed

Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 14:4284–4291CrossRefPubMed

Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR (2003) Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100:4138–4143CrossRefPubMed

Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW (2000) Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol 183:321–329CrossRefPubMed

Lui VW, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22:1–11PubMed

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021–3031CrossRefPubMed

Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath N, Tsai MH, Chang NW, Lin CF, Lin CC, Hsieh LJ, Wang TL, IeM Shih, Tsai FJ (2009) Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 69:2568–2576CrossRefPubMed

Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413–448CrossRefPubMed

Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375–391CrossRefPubMed

Vermorken JB (2005) Medical treatment in head and neck cancer. Ann Oncol 16(suppl 2):ii258–ii264CrossRefPubMed

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRefPubMed

Wen Y, Yan DH, Wang B, Spohn B, Ding Y, Shao R, Zou Y, Xie K, Hung MC (2001) p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res 61:7142–7147PubMed

Xia X, Lessor TJ, Cheng A, Zhang Y, Hamburger AW (2001) Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol 187:209–217CrossRefPubMed

Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefPubMed

Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, Hamburger AW (2000) Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer 82:683–690CrossRefPubMed

Yu Y, Chen W, Zhang Y, Hamburger A, Pan H, Zhang Z (2007) Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 Binding protein Ebp1 transfer. Int J Cancer 120:1909–1913CrossRefPubMed

Zhang Y, Fondell JD, Wang Q, Xia X, Cheng A, Lu ML, Hamburger AW (2002) Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene 21:5609–5618CrossRefPubMed

Title: Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer
Authors: Xu Zhou
Wantao Chen
Yuexing Zhang
Jian Sun
Qing Wang
Youcheng Yu
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0730-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer

Abstract

Objective

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2010

Development and characterization of a novel method for the analysis of gene expression patterns in lymphatic endothelial cells derived from primary breast tissues

Increased expression of cellular retinol-binding protein 1 in laryngeal squamous cell carcinoma

Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma

Expression of metalloproteases and their inhibitors in different histological types of breast cancer

Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB

Transformation potential of bone marrow stromal cells into undifferentiated high-grade pleomorphic sarcoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page